Japanese cosmetic maker Mandom expects to generate profit of JPY5bn

Published: 30-Oct-2014
Finance

The figure is expected to be higher than the forecast by JPY200m

You need to be a subscriber to read this article.
Click here to find out more.

Japanese cosmetic and hair products maker Mandom Corp. is expected to report an operating profit of roughly JPY5bn for the April-September half, higher than the forecast by JPY200m. However, the figure is down 7% on a year ago.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Finance

Mandom reports 4% rise in sales in 2015

Read more
Japanese cosmetics company sees strong growth at home and abroad

Trending Articles

  1. Estée Lauder Companies’ boss reveals reason why Puig merger talks failed Stéphane de La Faverie, the President and CEO of Estée Lauder Companies, has lifted the lid on negotiations between the two beauty giants and its approach to M&A
  2. LVMH names former Lancôme executive President of Sephora Collection Sylvia Tournery, former Global Deputy General Manager of L’Oréal-owned Lancôme, has been appointed President of LVMH’s Sephora Collection to drive its ‘next phase of growth’
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    E.l.f. Beauty is setting the standard for Trump tariff refunds. Will other brands lower their prices? E.l.f. Beauty plans to reinvest $58 million in US tariff refunds and reduce prices on certain products, after increasing the cost by $1 in 2025. But is it feasible for other beauty businesses to follow suit?
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    From Estée Lauder Companies to Glossier: 2026's biggest beauty job losses Economic challenges, acquisitions, administration troubles and a changing approach to purchasing products are some of the factors leading to mass job losses across the beauty industry at Estée Lauder Companies, Glossier and more
  5. Ulta Beauty sales top $3 billion in Q1 2026 as Space NK acquisition pays off Net sales increased 11.1% primarily due to increased comparable sales, as well as the acquisition of British high street beauty chain Space NK

Upcoming event

Anti-Ageing Skin Care Conference

23-24 June 2026 | London, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Finance

Mandom reports 4% rise in sales in 2015

Japanese cosmetics company sees strong growth at home and abroad
Finance

Japan’s Mandom puts business in India on hold

Mandom Corporation has decided to temporarily suspend its business in India
Regulatory

Revolution Beauty investigation closed by UK financial watchdog

Three years after launching a probe into cosmetics company Revolution Beauty, the UK’s Financial Conduct Authority is taking no further action
Manufacturing

Givaudan to take majority stake in Eurofragrance

Givaudan’s acquisition of a stake in the Spanish fragrance house is part of the Swiss ingredients supplier’s 2030 strategy
You need to be a subscriber to read this article.
Click here to find out more.
Skin Care

CeraVe Global Brand President Vincent Chauvière's plans to expand the brand's reach and influence

Chauvière, who formerly helped Vichy Laboratoires achieve impressive growth, plans to scale CeraVe’s creator-first communication strategy, with his first mark seen at the L’Oréal-owned drugstore brand’s Global CerAwards, as well as ramping up its expansion into sun care
Research & Development

Unilever opens India fragrance hub to enhance global capabilities

The new Unilever Fragrance House in Mumbai, India, forms part of the British conglomerate’s €100 million global investment to advance its in-house fragrance creation capabilities
Finance

L’Oréal Bold invests in South Korean biotech company Olix Pharmaceuticals

The Suwon-headquartered biotech company raised KRW 110bn in the funding round, and will use this to advance its ongoing small interfering RNAi-based projects
Subscribe now